BRCA1 and ovarian serous adenocarcinoma: In high-grade serous ovarian cancer, this vulnerability is often driven by defects in homologous recombination (HR), such as BRCA1/2 mutations, or BRCA reversion mutations that confer PARPi resistance (26–28).